Swainsonine affects the processing of glycoproteins in vivo.
Rats, sheep and guinea pigs treated with swainsonine excrete 'high mannose' oligosaccharides in urine. The major rat and guinea pig oligosaccharide is (Man)5GlcNAc, whereas sheep excrete a mixture of oligosaccharides of composition (Man)2-5GlcNAc2 and (Man)3-5GlcNAc. The presence of these oligosaccharides suggests that Golgi alpha-D-mannosidase II as well as lysosomal alpha-D-mannosidase is inhibited by swainsonine resulting in storage of abnormally processed asparagine-linked glycans from glycoproteins. Altered glycoprotein processing appears to have little effect on the health of the intoxicated animal, but the accompanying lysosomal storage produces a disease state.
D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D002855:Chromatography, Thin Layer; D008401:Gas Chromatography-Mass Spectrometry; D006023:Glycoproteins / Q000235:genetics*; D006168:Guinea Pigs; D009844:Oligosaccharides / Q000302:isolation & purification / Q000652:urine*; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012756:Sheep; D013045:Species Specificity; D017026:Swainsonine
D000470:Alkaloids; D006023:Glycoproteins; D009844:Oligosaccharides; D017026:Swainsonine